Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5?

Author:

Seabrook Amanda J12ORCID,Harris Jessica E3,Velosa Sofia B4,Kim Edward12,McInerney-Leo Aideen M5,Dwight Trisha12,Hockings Jason I6,Hockings Nicholas G7,Kirk Judy8,Leo Paul J9,Love Amanda J10,Luxford Catherine12,Marshall Mhairi9,Mete Ozgur1112,Pennisi David J9,Brown Matthew A13,Gill Anthony J21415,Hockings Gregory I1617,Clifton-Bligh Roderick J1218,Duncan Emma L9171920ORCID

Affiliation:

1. Cancer Genetics Laboratory, Kolling Institute, Royal North Shore Hospital, Sydney, Australia

2. Faculty of Medicine and Health, The University of Sydney, Sydney, Australia

3. The University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Woolloongabba, Australia

4. Noosa Hospital, Noosaville, Australia

5. Dermatology Research Centre, The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia

6. Dandenong Hospital, Dandenong, Australia

7. Science Department, Carey Baptist Grammar School, Kew, Australia

8. Familial Cancer Service, Westmead Hospital, Sydney, Australia

9. Australian Translational Genomics Centre, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology (QUT), Translational Research Institute, Woolloongabba, Australia

10. Department of Endocrinology, Royal Brisbane and Women’s Hospital, Herston, Australia

11. Department of Pathology, University Health Network, Toronto, Canada

12. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada

13. Guy’s and St Thomas’ NHS Foundation Trust and King’s College London NIHR Biomedical Research Centre, King’s College London, London, UK

14. NSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, Australia

15. Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia

16. Endocrinology Unit, Greenslopes Private Hospital, Brisbane, Australia

17. University of Queensland Faculty of Medicine, The University of Queensland, Brisbane, Australia

18. Department of Endocrinology, Royal North Shore Hospital, Sydney, Australia

19. Department of Twin Research & Genetic Epidemiology, School of Life Course Sciences, Faculty of Life Sciences and Medicine, King’s College London; St Thomas’ Campus, London, UK

20. Department of Endocrinology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

Abstract

Abstract Context Pathogenic germline MAX variants are associated with pheochromocytoma and paraganglioma (PPGL), pituitary neuroendocrine tumors and, possibly, other endocrine and nonendocrine tumors. Objective To report 2 families with germline MAX variants, pheochromocytomas (PCs) and multiple other tumors. Methods Clinical, genetic, immunohistochemical, and functional studies at University hospitals in Australia on 2 families with germline MAX variants undergoing usual clinical care. The main outcome measures were phenotyping; germline and tumor sequencing; immunohistochemistry of PC and other tumors; functional studies of MAX variants. Results Family A has multiple individuals with PC (including bilateral and metastatic disease) and 2 children (to date, without PC) with neuroendocrine tumors (paravertebral ganglioneuroma and abdominal neuroblastoma, respectively). One individual has acromegaly; immunohistochemistry of PC tissue showed positive growth hormone–releasing hormone staining. Another individual with previously resected PCs has pituitary enlargement and elevated insulin-like growth factor (IGF-1). A germline MAX variant (c.200C>A, p.Ala67Asp) was identified in all individuals with PC and both children, with loss of heterozygosity in PC tissue. Immunohistochemistry showed loss of MAX staining in PCs and other neural crest tumors. In vitro studies confirmed the variant as loss of function. In Family B, the proband has bilateral and metastatic PC, prolactin-producing pituitary tumor, multigland parathyroid adenomas, chondrosarcoma, and multifocal pulmonary adenocarcinomas. A truncating germline MAX variant (c.22G>T, p.Glu8*) was identified. Conclusion Germline MAX mutations are associated with PCs, ganglioneuromas, neuroblastomas, pituitary neuroendocrine tumors, and, possibly, parathyroid adenomas, as well as nonendocrine tumors of chondrosarcoma and lung adenocarcinoma, suggesting MAX is a novel multiple endocrine neoplasia gene.

Funder

Royal Brisbane and Women’s Hospital Foundation

Australian National Health and Medical Research Council

The Hillcrest Foundation

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Cited by 50 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3